Biodexa Pharmaceuticals
BDRX
7 hedge funds and large institutions have $228K invested in Biodexa Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
6.95% less ownership
Funds ownership: 9.86% → 2.9% (-7%)
13% less funds holding
Funds holding: 8 → 7 (-1)
67% less capital invested
Capital invested by funds: $693K → $228K (-$465K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$94K |
| 2 |
GI
GAMMA Investing
Foster City,
California
|
+$16.9K |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
+$70 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$24K |
| 2 |
AC
Armistice Capital
New York
|
-$3.49K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.78K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $159K | +$94K | +13,362 | +35% |
|
|
AC
2
Armistice Capital
New York
| $60.3K | -$3.49K | -496 | -2% |
|
|
GI
3
GAMMA Investing
Foster City,
California
| $8.52K | +$16.9K | +2,401 | +676% |
|
|
SS
4
SBI Securities
Tokyo,
Japan
| $93 | +$70 | +10 | +50% |
|
|
5
UBS Group
Zurich,
Switzerland
| $78 | -$2.78K | -395 | -94% |
|
|
HHCP
6
Hilton Head Capital Partners
Hilton Head Island,
South Carolina
| $19 | – | – | – |
|
|
7
RhumbLine Advisers
Boston,
Massachusetts
| $11 | -$7 | -1 | -20% |
|
|
CIAM
8
Caitong International Asset Management
Hong Kong
| $1 | – | – | – |
|
|
HF
9
HRT Financial
New York
| – | -$24K | -2,117 | Closed |
|
BDRX Hedge Fund Activity: Q1 2026 in Review
7 of the 8,161 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q1 2026, worth a combined $228K — down 67% from $693K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BDRX and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, adding an estimated $94K. The largest seller was HRT Financial, exiting entirely with an estimated $24K sold.
- 7 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q1 2026, down from 8 in Q4 2025.
- Funds reported $228K of Biodexa Pharmaceuticals stock for Q1 2026, down 67% quarter-over-quarter.
- 0 funds opened new Biodexa Pharmaceuticals positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest Biodexa Pharmaceuticals buyer in Q1 2026 was Sabby Management, an estimated $94K added.
- The largest Biodexa Pharmaceuticals seller in Q1 2026 was HRT Financial, an estimated $24K sold.
Based on aggregated 13F filings for Q1 2026.